ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5178ometendo-5178Research ArticleСтатьиArticlesКлиническая, метаболическая и гормональнаяэффективность применения Орлистата у пациентовс метаболическим синдромомKlinicheskaya, metabolicheskaya i gormonal'nayaeffektivnost' primeneniya Orlistata u patsientovs metabolicheskim sindromomErshovaE V-KolesnikovaG S-ButrovaS A-20041503200411№1 (2004)3437Copyright © Ershova E.V., Kolesnikova G.S., Butrova S.A., 20042004Ershova E.V., Kolesnikova G.S., Butrova S.A.Ershova E.V., Kolesnikova G.S., Butrova S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5178ReferencesБутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. РМЖ. 2001; 2(9):56-60.Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. РМЖ. 2001; 2(9):56-60.Мкртумян А.М. Ксеникал в комплексной терапии метаболического синдрома. РМЖ. 2001; 2(9):72-73.Мкртумян А.М. Ксеникал в комплексной терапии метаболического синдрома. РМЖ. 2001; 2(9):72-73.Cada DJ, Baker DE, Levien T. Orlistat. Hosp Pharm. 1999; 34:1195-213.Cada DJ, Baker DE, Levien T. Orlistat. Hosp Pharm. 1999; 34:1195-213.Colditz GA, Willet WC et al. Weight gain as risk factors for clinical diabetes mellitus in women. Ann Int Med. 1995; 122:481-6.Colditz GA, Willet WC et al. Weight gain as risk factors for clinical diabetes mellitus in women. Ann Int Med. 1995; 122:481-6.Davison MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduc- tion in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999; 281:235-42.Davison MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduc- tion in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999; 281:235-42.Despres JP, Krauss RM. Obesity and lipoprotein metabolism. In: Bray GA, Bouchard C, James WPT, eds. Handbook of Obesity. New York, NY: Marcel Dekker; 1998; 651-675Despres JP, Krauss RM. Obesity and lipoprotein metabolism. In: Bray GA, Bouchard C, James WPT, eds. Handbook of Obesity. New York, NY: Marcel Dekker; 1998; 651-675European Multicentre Orlistat Study Group. Randomised placebo- controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998; 352:167-72.European Multicentre Orlistat Study Group. Randomised placebo- controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998; 352:167-72.Finer N, James WPT, Kopelman PG et al. One-year treatment of obesity: a random- ized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase ingibitor. Int J Obes. 2000; 24:306-313.Finer N, James WPT, Kopelman PG et al. One-year treatment of obesity: a random- ized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase ingibitor. Int J Obes. 2000; 24:306-313.Hauptman J, Lucas C, Boldrin MN et al. Orlistat in the long-term treatment of obesi- ty in primary care settings. Arch Fam Med. 2000; 9:160-7.Hauptman J, Lucas C, Boldrin MN et al. Orlistat in the long-term treatment of obesi- ty in primary care settings. Arch Fam Med. 2000; 9:160-7.Heymsfield SB, Segal KR, Hauptman J at al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000; 5(8):1321-6.Heymsfield SB, Segal KR, Hauptman J at al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000; 5(8):1321-6.Hill JO, Hauptman J, Anderson JW et al. Orlistat, a lipase inhibitor, for weight main- tenance after conventional dieting: one 1-y study. Am J Clin Nutr. 1999; 69:1108-16.Hill JO, Hauptman J, Anderson JW et al. Orlistat, a lipase inhibitor, for weight main- tenance after conventional dieting: one 1-y study. Am J Clin Nutr. 1999; 69:1108-16.Rossner S, Sjostrom L, Noack R et al. Weight Loss, Weight Maintenance, and Improved Cardiovascular Risk Factors after 2 Years Treatment with Orlistat for Obesity. Obes Res. 2000; 8(1):49-61.Rossner S, Sjostrom L, Noack R et al. Weight Loss, Weight Maintenance, and Improved Cardiovascular Risk Factors after 2 Years Treatment with Orlistat for Obesity. Obes Res. 2000; 8(1):49-61.Symposium "Orlistat: Ein neuer Ansatz in der Behandlung des adipoesen Typ-2- Diabetikers", im Rahmen der 33.Jahrestagung der Deutschen Diabetes Gesellschaft, May 1998, Leipzig.Symposium "Orlistat: Ein neuer Ansatz in der Behandlung des adipoesen Typ-2- Diabetikers", im Rahmen der 33.Jahrestagung der Deutschen Diabetes Gesellschaft, May 1998, Leipzig.Targenson JS. XENDOS - a Unique Advantage Abstract Book Satellite Symp, May 2003, Helsinki.Targenson JS. XENDOS - a Unique Advantage Abstract Book Satellite Symp, May 2003, Helsinki.Unger RH. Lipotoxic Diseases. Annu Rev Med. 2002; 53:319-36.Unger RH. Lipotoxic Diseases. Annu Rev Med. 2002; 53:319-36.
The authors declare that there are no conflicts of interest present.